<DOC>
	<DOCNO>NCT00887770</DOCNO>
	<brief_summary>This study perform investigate potential AZD5672 affect electrical conduction pathway heart . AZD5672 compare drug ( moxifloxacin - license antibiotic ) know detectable safe change electrical conduction heart .</brief_summary>
	<brief_title>A Study Investigate Potential AZD5672 Affect Electrical Conduction Pathways Heart</brief_title>
	<detailed_description />
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>N- ( 1- ( 3- ( 3,5-difluorophenyl ) -3- ( 4-methanesulfonylphenyl ) propyl ) piperidin-4-yl ) -N-ethyl-2- ( 4-methanesulfonylphenyl ) acetamide</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Body Mass Index ( BMI ) 18 30 kg/m2 minimum weight 50kg . Nonsmoker Marked QTc prolongation baseline e.g . repeat demonstration QTc interval &gt; 450ms marked shorten QTcF &lt; 350ms Any clinically important abnormality rhythm , conduction morphology rest ECG may interfere interpretation QTc Interval change Use concomitant medication prolong QT/QTc interval</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>QTcF</keyword>
	<keyword>Crossover</keyword>
	<keyword>ICH E14</keyword>
	<keyword>QT/QTc prolongation</keyword>
	<keyword>Moxifloxacin</keyword>
	<keyword>QT/QTc Interval</keyword>
</DOC>